Blueprint Medicines Co. (NASDAQ:BPMC) Position Increased by Swiss National Bank

Swiss National Bank boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 7.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 124,600 shares of the biotechnology company's stock after acquiring an additional 8,400 shares during the period. Swiss National Bank owned 0.20% of Blueprint Medicines worth $10,868,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Empirical Asset Management LLC acquired a new position in Blueprint Medicines in the 4th quarter valued at about $2,348,000. Stephens Inc. AR purchased a new position in shares of Blueprint Medicines during the fourth quarter valued at approximately $321,000. Massachusetts Financial Services Co. MA boosted its position in Blueprint Medicines by 48.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company's stock worth $23,332,000 after acquiring an additional 82,693 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Blueprint Medicines by 2.4% in the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock worth $26,465,000 after acquiring an additional 7,101 shares during the period. Finally, KBC Group NV raised its holdings in Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 1,023 shares during the last quarter.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares of the company's stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ariel Hurley sold 2,250 shares of the business's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the sale, the insider now owns 14,967 shares of the company's stock, valued at $1,496,700. This trade represents a 13.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,334 shares of company stock valued at $3,103,512 over the last ninety days. Corporate insiders own 4.21% of the company's stock.

Remove Ads

Blueprint Medicines Stock Up 7.4 %

Shares of Blueprint Medicines stock traded up $6.55 during trading hours on Monday, hitting $95.27. 1,358,865 shares of the company's stock traded hands, compared to its average volume of 711,535. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The company has a market cap of $6.09 billion, a PE ratio of -88.21 and a beta of 0.58. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a 50 day simple moving average of $99.47 and a 200-day simple moving average of $93.89.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities research analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BPMC has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an "outperform" rating for the company. JMP Securities reiterated a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Piper Sandler boosted their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $133.00 price target on shares of Blueprint Medicines in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Blueprint Medicines has an average rating of "Moderate Buy" and an average target price of $124.95.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.